Pseudoprogression of Melanoma Brain Metastases

Jillian L. Simard, Melanie Smith, Sunandana Chandra*

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of Review: Immune checkpoint inhibitors are increasingly being used to treat melanoma brain metastases. One potential complication of immune checkpoint inhibitors is a phenomenon called pseudoprogression, in which a tumor transiently increases in size due to lymphocyte infiltration. This article reviews the characteristics of pseudoprogression and their clinical implications. Recent Findings: Pseudoprogression can be challenging to differentiate from true progression noted clinically or radiographically, thereby complicating management decisions and potentially confusing patients and their families. The transient tumor enlargement can also cause symptoms that mimic true tumor progression. Summary: Because the use of immunotherapy on melanoma brain metastases is a relatively new treatment paradigm, there is limited evidence to guide clinical decision-making and prognostication related to pseudoprogression.

Original languageEnglish (US)
Article number91
JournalCurrent Oncology Reports
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Melanoma
Neoplasm Metastasis
Brain
Neoplasms
Immunotherapy
Lymphocytes
Therapeutics
Clinical Decision-Making

Keywords

  • Brain metastasis
  • Immunotherapy
  • Melanoma
  • Pseudoprogression

ASJC Scopus subject areas

  • Oncology

Cite this

Simard, Jillian L. ; Smith, Melanie ; Chandra, Sunandana. / Pseudoprogression of Melanoma Brain Metastases. In: Current Oncology Reports. 2018 ; Vol. 20, No. 11.
@article{8d522eb829d1492686aa3231bad26068,
title = "Pseudoprogression of Melanoma Brain Metastases",
abstract = "Purpose of Review: Immune checkpoint inhibitors are increasingly being used to treat melanoma brain metastases. One potential complication of immune checkpoint inhibitors is a phenomenon called pseudoprogression, in which a tumor transiently increases in size due to lymphocyte infiltration. This article reviews the characteristics of pseudoprogression and their clinical implications. Recent Findings: Pseudoprogression can be challenging to differentiate from true progression noted clinically or radiographically, thereby complicating management decisions and potentially confusing patients and their families. The transient tumor enlargement can also cause symptoms that mimic true tumor progression. Summary: Because the use of immunotherapy on melanoma brain metastases is a relatively new treatment paradigm, there is limited evidence to guide clinical decision-making and prognostication related to pseudoprogression.",
keywords = "Brain metastasis, Immunotherapy, Melanoma, Pseudoprogression",
author = "Simard, {Jillian L.} and Melanie Smith and Sunandana Chandra",
year = "2018",
month = "11",
day = "1",
doi = "10.1007/s11912-018-0722-x",
language = "English (US)",
volume = "20",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "11",

}

Pseudoprogression of Melanoma Brain Metastases. / Simard, Jillian L.; Smith, Melanie; Chandra, Sunandana.

In: Current Oncology Reports, Vol. 20, No. 11, 91, 01.11.2018.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pseudoprogression of Melanoma Brain Metastases

AU - Simard, Jillian L.

AU - Smith, Melanie

AU - Chandra, Sunandana

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Purpose of Review: Immune checkpoint inhibitors are increasingly being used to treat melanoma brain metastases. One potential complication of immune checkpoint inhibitors is a phenomenon called pseudoprogression, in which a tumor transiently increases in size due to lymphocyte infiltration. This article reviews the characteristics of pseudoprogression and their clinical implications. Recent Findings: Pseudoprogression can be challenging to differentiate from true progression noted clinically or radiographically, thereby complicating management decisions and potentially confusing patients and their families. The transient tumor enlargement can also cause symptoms that mimic true tumor progression. Summary: Because the use of immunotherapy on melanoma brain metastases is a relatively new treatment paradigm, there is limited evidence to guide clinical decision-making and prognostication related to pseudoprogression.

AB - Purpose of Review: Immune checkpoint inhibitors are increasingly being used to treat melanoma brain metastases. One potential complication of immune checkpoint inhibitors is a phenomenon called pseudoprogression, in which a tumor transiently increases in size due to lymphocyte infiltration. This article reviews the characteristics of pseudoprogression and their clinical implications. Recent Findings: Pseudoprogression can be challenging to differentiate from true progression noted clinically or radiographically, thereby complicating management decisions and potentially confusing patients and their families. The transient tumor enlargement can also cause symptoms that mimic true tumor progression. Summary: Because the use of immunotherapy on melanoma brain metastases is a relatively new treatment paradigm, there is limited evidence to guide clinical decision-making and prognostication related to pseudoprogression.

KW - Brain metastasis

KW - Immunotherapy

KW - Melanoma

KW - Pseudoprogression

UR - http://www.scopus.com/inward/record.url?scp=85056352108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056352108&partnerID=8YFLogxK

U2 - 10.1007/s11912-018-0722-x

DO - 10.1007/s11912-018-0722-x

M3 - Review article

VL - 20

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 11

M1 - 91

ER -